CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
0.780
-0.036 (-4.42%)
Feb 21, 2025, 4:00 PM EST - Market closed
CytomX Therapeutics Employees
As of December 31, 2023, CytomX Therapeutics had 122 total employees, including 120 full-time and 2 part-time employees. The number of employees increased by 4 or 3.39% compared to the previous year.
Employees
122
Change (1Y)
4
Growth (1Y)
3.39%
Revenue / Employee
$1,037,844
Profits / Employee
$113,361
Market Cap
61.04M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CTMX News
- 6 weeks ago - CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - GlobeNewsWire
- 3 months ago - CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 3 months ago - CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors - GlobeNewsWire
- 7 months ago - CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
- 8 months ago - CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer - GlobeNewsWire